SCHEMBL5656355

SCHEMBL5656355

COc1ccccc1NC(=O)OCCCN1CCN(c2ccccn2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
KDM4E B2RXH2 1/20 0.64
USP2 O75604 1/20 0.64
TSHR P16473 1/20 0.64
HSD17B10 Q99714 1/20 0.64
HTR1A P08908 4/20 0.60
HTR2A P28223 3/20 0.60
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HRH3 Q9Y5N1 3/20 0.57
ADRA1D P25100 2/20 0.55
ADRA1A P35348 2/20 0.55
ADRA1B P35368 2/20 0.55
DRD2 P14416 2/20 0.53
HTR7 P34969 2/20 0.53
DRD3 P35462 2/20 0.53
ADRA2C P18825 1/20 0.53
DRD1 P21728 1/20 0.53
DRD5 P21918 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655631 0.94 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5657710 0.91 HTR1A (0.59) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5659501 0.90 KDM4E (0.58) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5657438 0.89 HRH3 (0.56) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5656326 0.88 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5656283 0.85 ADRA1D (0.54) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL5658252 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KDM4EUSP2TSHR
SCHEMBL5659290 0.84 HTR4 (0.54) ALDH1A1SMN1; SMN2TSHRHTR1AMEN1
SCHEMBL5655841 0.84 ADRA1A (0.71) ALDH1A1KDM4EHTR1AHTR2AADRA1D
SCHEMBL5657864 0.84 L3MBTL1 (0.59) ALDH1A1TSHRHTR1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C ALDH1A1 1018/4885SMN1; SMN2 3970/4885KDM4E 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.